Oral News and Research

RSS

Cantrixil proves highly effective at killing human ovarian stem cells in pre-clinical study

US-Australian drug discovery company, Novogen Ltd, and its subsidiary, CanTx, Inc., and Yale University, on March 27 released pre-clinical data on experimental anti-cancer drug, Cantrixil. The data was presented as an oral presentation by Professor Gil Mor MD PhD of Yale Medical School to the 62nd Annual Scientific Meeting of the Society of Reproductive Investigation in San Francisco, CA.

30 Mar 2015

Caris Life Sciences study may have potentially significant benefit in patients with uterine cancer

Caris Life Sciences today announced the presentation of a study that found drugs targeting specific pathways may have potentially significant benefit in a select subset of patients with uterine cancer. The study results were highlighted today in an oral presentation in a Plenary Session at the Society of Gynecologic Oncology 2015 Annual Meeting on Women's Cancer in Chicago, Ill.

30 Mar 2015

DURECT initiates DUR-928 multi-dose Phase 1 clinical trial for NAFLD, NASH and AKI

DURECT Corporation today announced that it has initiated a multi-dose Phase 1 clinical trial of an oral formulation of DUR-928, the lead molecule in DURECT's Epigenomic Regulator Program.

30 Mar 2015

Synthetic Biologics begins SYN-004 Phase 2a clinical trial to prevent C. difficile infection

Synthetic Biologics, Inc., a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced the initiation of a Phase 2a clinical trial to evaluate the gastrointestinal (GI) antibiotic-degrading effects and the safety of SYN-004, the Company's investigational oral beta-lactamase enzyme designed to protect the microbiome and prevent C. difficile infection (CDI).

30 Mar 2015

Medunik announces availability of PHEBURANE drug in Canada for chronic management of UCD

Medunik Canada, a Canadian pharmaceutical company specialized in rare diseases, is pleased to announce that PHEBURANE (a tasteless oral formulation of sodium phenylbutyrate), is now available for distribution in Canada. PHEBURANE is the first drug to be approved in Canada for the chronic management of urea cycle disorders (UCD) after receiving market authorisation on January 27th, 2015.

30 Mar 2015

UAB scientist explores the bone development function of runx2 gene

Amjad Javed, Ph.D., of the University of Alabama at Birmingham, has taken a major step forward in understanding the bone development function of a gene called runx2, which could lead to future ways to speed bone healing, aid bone bioengineering, stem osteoporosis and reduce arthritis.

30 Mar 2015

Top experts focus on musculoskeletal disorders in open key Congress in Milan

Musculoskeletal conditions, which affect over 1.7 billion people worldwide, will be the focus of a major four-day Congress which opens today in Milan, Italy.

30 Mar 2015

Roseroot extract may be beneficial for treating major depressive disorder

Rhodiola rosea (R. rosea), or roseroot, may be a beneficial treatment option for major depressive disorder (MDD), according to results of a study in the journal Phytomedicine led by Jun J. Mao, MD, MSCE, associate professor of Family Medicine, Community Health and Epidemiology and colleagues at the Perelman School of Medicine of University of Pennsylvania.

27 Mar 2015

Data demonstrates benefits associated with use of EXPAREL in hip, knee replacement patients

Pacira Pharmaceuticals, Inc. today announced data demonstrating the benefits associated with the use of EXPAREL (bupivacaine liposome injectable suspension) in a study of over 2,200 hip and knee replacement patients.

27 Mar 2015

Transition announces positive results from ELND005 AME and renal clearance studies

Transition Therapeutics Inc. today announced results from two phase 1 clinical studies of neuropsychiatric drug candidate ELND005. These studies, an absorption-metabolism-excretion ("AME") study and a renal clearance study, are specialized clinical pharmacology trials that are required by the United States Food and Drug Administration for the approval of most drugs in development.

26 Mar 2015

Arno Therapeutics' AR-42 with cisplatin demonstrates anti-tumor effect in bladder cancer models

Arno Therapeutics, Inc., a clinical stage biopharmaceutical company primarily focused on the development of oncology therapeutics, today announced that data from a preclinical study demonstrate its histone-deacetylase (HDAC) inhibitor AR-42 in combination with cisplatin has a synergistic anti-tumor effect in bladder cancer models.

26 Mar 2015

Alternating sunitinib, everolimus not supported in advanced RCC

Australian researchers report that an alternating regimen of sunitinib and everolimus, although feasible and low-risk in patients with advanced renal cell carcinoma, failed to meet the prespecified criteria for use or continued development.

25 Mar 2015

Egalet announces plans to commercialize SPRIX Nasal Spray and OXAYDO tablets

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today announced its plans for the commercialization of SPRIX (ketorolac tromethamine) Nasal Spray and OXAYDO (oxycodone HCI, USP) tablets for oral use only –CII.

25 Mar 2015

Boston Scientific announces successful implantations of WATCHMAN Device in three US patients

This week, three patients in the United States received the first implants of the Boston Scientific Corporation WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device.

25 Mar 2015

Duke researchers develop new model to study why some HPV infections go away and others progress

For people infected with the human papilloma virus (HPV), the likelihood of clearing the infection and avoiding HPV-related cancer may depend less on the body's disease-fighting arsenal than has been generally assumed.

25 Mar 2015

TB Alliance receives Australian DFAT grant to support late-stage clinical trials of new TB drugs

TB Alliance, a not-for-profit product development partnership with the mission of developing better, faster, and affordable drugs for tuberculosis (TB), has received a grant from the Australian Department of Foreign Affairs and Trade to support late-stage clinical trials of new TB treatments.

25 Mar 2015

Cipher to distribute Can-Fite’s CF101 for plaque psoriasis and rheumatoid arthritis treatment in Canada

Cipher Pharmaceuticals Inc. today announced it has licensed the Canadian distribution rights to CF101, a novel chemical entity being developed by Can-Fite Biopharma for moderate to severe plaque psoriasis and rheumatoid arthritis.

23 Mar 2015

Acne patients not getting medications prescribed by their dermatologists

Medicine obviously can't do much good if it sits on a pharmacy shelf. Yet more than one-quarter of the acne patients surveyed by Wake Forest Baptist Medical Center researchers didn't get medications prescribed by their dermatologists.

23 Mar 2015

Study explains why generic insulin remains out of reach for diabetes patients

A generic version of insulin, the lifesaving diabetes drug used by 6 million people in the United States, has never been available in this country because drug companies have made incremental improvements that kept insulin under patent from 1923 to 2014.

23 Mar 2015

MED15 may serve as prognostic marker for HNSCC recurrence

A new study provides the first evidence that the mediator complex subunit 15 (MED15) may play a crucial role in the pathophysiology of head and neck squamous cell carcinoma (HNSCC). MED15 overexpression was found to be associated with higher mortality rates in HNSCC patients with cancer recurrence, particularly in oral cavity/oropharyngeal tumors, according to the study published in The American Journal of Pathology.

21 Mar 2015

Oral News and Research

Cantrixil proves highly effective at killing human ovarian stem cells in pre-clinical study

Caris Life Sciences study may have potentially significant benefit in patients with uterine cancer

DURECT initiates DUR-928 multi-dose Phase 1 clinical trial for NAFLD, NASH and AKI

Synthetic Biologics begins SYN-004 Phase 2a clinical trial to prevent C. difficile infection

Medunik announces availability of PHEBURANE drug in Canada for chronic management of UCD

UAB scientist explores the bone development function of runx2 gene

Top experts focus on musculoskeletal disorders in open key Congress in Milan

Roseroot extract may be beneficial for treating major depressive disorder

Data demonstrates benefits associated with use of EXPAREL in hip, knee replacement patients

Transition announces positive results from ELND005 AME and renal clearance studies

Arno Therapeutics' AR-42 with cisplatin demonstrates anti-tumor effect in bladder cancer models

Alternating sunitinib, everolimus not supported in advanced RCC

Egalet announces plans to commercialize SPRIX Nasal Spray and OXAYDO tablets

Boston Scientific announces successful implantations of WATCHMAN Device in three US patients

Duke researchers develop new model to study why some HPV infections go away and others progress

TB Alliance receives Australian DFAT grant to support late-stage clinical trials of new TB drugs

Cipher to distribute Can-Fite’s CF101 for plaque psoriasis and rheumatoid arthritis treatment in Canada

Acne patients not getting medications prescribed by their dermatologists

Study explains why generic insulin remains out of reach for diabetes patients

MED15 may serve as prognostic marker for HNSCC recurrence

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News